

Tissue Diagnostics Market - Forecasts from 2020 to 2025

<https://marketpublishers.com/r/T906A301D8ADEN.html>

Date: August 2020

Pages: 122

Price: US\$ 3,950.00 (Single User License)

ID: T906A301D8ADEN

Abstracts

The tissue diagnostics market is projected to grow at a CAGR of 7.16% to reach US\$6.385 billion by 2025 from US\$4.216 billion in 2019. Cancer is a major public health and economic issue and its burden is set to spiral. With over 18 million cases in 2018, 29 million cases by 2040 are expected due to the aging and growth of the population [Source: WHO]. Recognized as one of the global standards for cancer diagnosis, tissue diagnostics are integral to obtain the biological aspects of tumors. Moreover, with an increased incidence of cancer, the market for tissue diagnostics markets has witnessed a promising growth and is further estimated to grow during the forecast period. Moreover, there is a growing adoption rate pertaining to the automated tissue-based diagnostic systems due to its reported capabilities of swift diagnosis of tumors, by research institutions. For example, F. Hoffmann-La Roche Ltd partnered with West Clinic Cancer Center in 2019 with the objective to enhance patient care by employing Roche's BenchMark ULTRA Automated Advanced Staining System that is used for immunohistochemical testing or in-situ hybridization enabling a faster diagnosis of tumors. Moreover, the revenue generation in the market is being propelled by the increasing focus of prime market players to develop advanced tissue-diagnostic based companion diagnostic tests. To this end, PD-L1 IHC 22C3 pharmDx assay, which is a qualitative immunohistochemical assay to identify non-small cell lung cancer, that was designed by Agilent in partnership with Merck received the FDA approval. Moreover, the anatomic pathology workflow is consistently evolving and are gradually being automated to a great extent. This transition from manual to automation is giving rise to novel solutions. Further, the rise in the standardization of processes in laboratories concomitantly the incorporation of automated molecular diagnostic technologies and incorporation of bioinformatics have led to a paradigm shift in pathology workflow and has enabled clinicians to prioritize critical cases, reduce the turnaround time and enhance patient outcomes. To this extent, in 2019, Alverno Laboratories in partnership

with Royal Phillips integrated Philips' IntelliSite Pathology Solution in the clinical laboratories intending to improve laboratory efficiency, quality, and patient safety which exemplifies the benefits of adoption of digital pathology solution thereby contributing to the surge in the segment. In view of the above it is expected that during the forecast period, the technology segment of digital pathology will witness a meteoric growth. This is also in part due to the growing preference rate of whole-slide imaging (WSI) among the pathologies, which is one of the prime factors responsible for the growth of this subsegment. The rationale behind such a preference is that specific features of tumors can now be extracted by WSI thereafter enabling the quantification of each component of the features and support diagnosis of cancer simultaneously provide a clinical diagnosis of tumors. For example, Nikon Instruments Inc. launched a digital slide scanning system, OS-15-N, in partnership with OpraSCAN. In 2019. Again, during the same year, IntelliSite Pathology Solution by Philips was introduced across India by the HealthCare Global Enterprises Ltd.

In view of the application, the segment of Lung cancer is the most commonly diagnosed cancer and the leading cause of cancer death worldwide followed by breast cancer. Regarding both sexes combined, globally, lung cancer continues to be the most commonly diagnosed cancer (2.1 million, 12% of the total) and the leading cause of cancer death (1.8 million, 18%) because of its poor prognosis. Female breast cancer is the second most common cancer overall (2.1 million, 12%) but the fifth leading cause of cancer death (627,000, 7%) because of its relatively favorable prognosis. As such, it is the most prevalent cancer worldwide (6.9 million women living within 5 years of their breast cancer diagnosis. About one in twenty females will be diagnosed with breast cancer throughout their lifetime, although this number varies significantly by country. 2 Incidence rates are elevated in Australia/New Zealand, Europe, and North America, notably in Belgium (113 cases per 100,000 female population) and Luxembourg (109) in Europe, and Australia (94). In contrast, incidence rates in sub-Saharan African regions, particularly in Eastern (30 cases per 100,000 female population) and Middle Africa (28), as well as South-Central Asia (26), were considerably lower. Further, the lifetime risk of breast cancer among females in high-income countries can be up to three times that in low-income countries [Source: WHO]. To this end, in 2020 Exact Sciences Corp. (NASDAQ: EXAS) announced that it would be presenting data to demonstrate the clinical value of the Oncotype DX Breast Recurrence Score® test and exemplify the research progress made by Exact Sciences' Mayo Clinic collaboration toward smarter solutions across the cancer continuum. Further, during the same year, OncBioMune Pharmaceuticals, Inc. (OTC PINK: OBMP) announced the successful completion of its purchase of all the assets of Avant Diagnostics, Inc. which provides personalized medicine data through its Theralink ®assays, initially for breast cancer, to assist the

treating physician in a data-driven process for treatment decision support and to help enable predictive biomarker-based patient therapy selection. Besides development pertaining to breast cancers, during the same year, Veracyte, Inc. (Nasdaq: VCYT) which is a global genomic diagnostics company, announced that De Novo classification request to the U.S. Food & Drug Administration (FDA) for the nCounter[®] Dx LymphMark[™] Assay, a novel, genomic lymphoma subtyping test.

Segmentation

By Product

Consumables

Antibodies

Kits

Probes

Reagents

Instruments

Slide Scanners

Slide Staining Systems

Tissue Microarrays

Tissue Processing Systems

Other Products

By Technology

Digital Pathology and Workflow Management

Immunohistochemistry (IHC)

In Situ Hybridization (ISH)

Primary Special Staining

By Application

Breast cancer

Cervical cancer

Colorectal cancer

Gastric cancer

Lung cancer

Others

By End-Users

Contract Research Organizations (CROs)

Hospitals

Pharmaceutical Organizations

Research Laboratories

By Geography

North America

USA

Canada

Mexico

South America

Brazil

Argentina

Others

Europe

Germany

France

United Kingdom

Italy

Others

The Middle East and Africa

Israel

Saudi Arabia

Others

Asia Pacific

China

Japan

South Korea

India

Others

Contents

1. INTRODUCTION

- 1.1. Market Definition
- 1.2. Market Segmentation

2. RESEARCH METHODOLOGY

- 2.1. Research Data
- 2.2. Assumptions

3. EXECUTIVE SUMMARY

- 3.1. Research Highlights

4. MARKET DYNAMICS

- 4.1. Market Drivers
- 4.2. Market Restraints
- 4.3. Porters Five Forces Analysis
 - 4.3.1. Bargaining Power of Suppliers
 - 4.3.2. Bargaining Power of Buyers
 - 4.3.3. The threat of New Entrants
 - 4.3.4. Threat of Substitutes
 - 4.3.5. Competitive Rivalry in the Industry
- 4.4. Industry Value Chain Analysis

5. TISSUE DIAGNOSTICS MARKET, BY TYPE

- 5.1. Introduction
- 5.2. Consumables
 - 5.2.1. Antibodies
 - 5.2.2. Kits
 - 5.2.3. Probes
 - 5.2.4. Reagents
- 5.3. Instruments
 - 5.3.1. Slide Scanners
 - 5.3.2. Slide Staining Systems

- 5.3.3. Tissue Microarrays
- 5.3.4. Tissue Processing Systems
- 5.3.5. Others

6. TISSUE DIAGNOSTICS MARKET ANALYSIS, BY TECHNOLOGY

- 6.1. Introduction
- 6.2. Digital Pathology and Workflow Management
- 6.3. Immunohistochemistry (IHC)
- 6.4. In Situ Hybridization (ISH)
- 6.5. Primary Special Staining

7. TISSUE DIAGNOSTICS MARKET ANALYSIS, BY APPLICATION

- 7.1. Introduction
- 7.2. Breast cancer
- 7.3. Cervical cancer
- 7.4. Colorectal cancer
- 7.5. Gastric cancer
- 7.6. Lung cancer
- 7.7. Others

8. TISSUE DIAGNOSTICS MARKET ANALYSIS, BY END-USER

- 8.1. Introduction
- 8.2. Contract Research Organizations (CROs)
- 8.3. Hospitals
- 8.4. Pharmaceutical Organizations
- 8.5. Research Laboratories

9. TISSUE DIAGNOSTICS MARKET ANALYSIS, BY GEOGRAPHY

- 9.1. Introduction
- 9.2. North America
 - 9.2.1. North America Tissue Diagnostics Market Analysis, By Product
 - 9.2.2. North America Tissue Diagnostics Market Analysis, By Technology
 - 9.2.3. North America Tissue Diagnostics Market Analysis, By Application
 - 9.2.4. North America Tissue Diagnostics Market Analysis, By End-Users
 - 9.2.5. By Country

9.2.5.1. USA

9.2.5.2. Canada

9.2.5.3. Mexico

9.3. South America

9.3.1. South America Tissue Diagnostics Market Analysis, By Product

9.3.2. South America Tissue Diagnostics Market Analysis, By Technology

9.3.3. South America Tissue Diagnostics Market Analysis, By Application

9.3.4. South America Tissue Diagnostics Market Analysis, By End-Users

9.3.5. By Country

9.3.5.1. Brazil

9.3.5.2. Argentina

9.3.5.3. Others

9.4. Europe

9.4.1. Europe Tissue Diagnostics Market Analysis, By Product

9.4.2. Europe Tissue Diagnostics Market Analysis, By Technology

9.4.3. Europe Tissue Diagnostics Market Analysis, By Application

9.4.4. Europe Tissue Diagnostics Market Analysis, By End-Users

9.4.5. By Country

9.4.5.1. Germany

9.4.5.2. France

9.4.5.3. United Kingdom

9.4.5.4. Italy

1.1.1.1. Others

9.5. The Middle East and Africa

9.5.1. Middle East and Africa Tissue Diagnostics Market Analysis, By Product

9.5.2. Middle East and Africa Tissue Diagnostics Market Analysis, By Technology

9.5.3. Middle East and Africa Tissue Diagnostics Market Analysis, By Application

9.5.4. Middle East and Africa Tissue Diagnostics Market Analysis, By End-Users

9.5.5. By Country

9.5.5.1. Israel

9.5.5.2. Saudi Arabia

9.5.5.3. Others

9.6. Asia Pacific

9.6.1. Asia Pacific Tissue Diagnostics Market Analysis, By Product

9.6.2. Asia Pacific Tissue Diagnostics Market Analysis, By Technology

9.6.3. Asia Pacific Tissue Diagnostics Market Analysis, By Application

9.6.4. Asia Pacific Tissue Diagnostics Market Analysis, By End-Users

9.6.5. By Country

9.6.5.1. China

- 9.6.5.2. Japan
- 9.6.5.3. South Korea
- 9.6.5.4. India
- 9.6.5.5. Others

10. COMPETITIVE ENVIRONMENT AND ANALYSIS

- 10.1. Major Players and Strategy Analysis
- 10.2. Emerging Players and Market Lucrativeness
- 10.3. Mergers, Acquisitions, Agreements, and Collaborations
- 10.4. Vendor Competitiveness Matrix

11. COMPANY PROFILES

- 11.1. Abbott Laboratories
- 11.2. Agilent Technologies, Inc.
- 11.3. AstraZeneca 2020
- 11.4. BD
- 11.5. BioGenex
- 11.6. Cancer Genetics, Inc.
- 11.7. Cardinal Health
- 11.8. Danaher
- 11.9. Exact Sciences Corporation
- 11.10. F. Hoffmann-La Roche Ltd
- 11.11. Genemed Biotechnologies, Inc.
- 11.12. Greiner Bio One International GmbH
- 11.13. McKesson Medical-Surgical Inc.
- 11.14. Medtronic
- 11.15. Merck KGaA
- 11.16. QIAGEN
- 11.17. SARSTEDT AG & Co. KG
- 11.18. Thermo Fisher Scientific Inc.

I would like to order

Product name: Tissue Diagnostics Market - Forecasts from 2020 to 2025

Product link: <https://marketpublishers.com/r/T906A301D8ADEN.html>

Price: US\$ 3,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/T906A301D8ADEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970